Ampol Ltd (ASX: ALD) share price is in focus today after the company announced a new A$400 million delayed-draw subordinated notes facility, following successful previous issues in 2025. This new facility supports Ampol’s ongoing capital management and provides flexible, long-term funding options.

What did Ampol report?

• Launched a wholesale offer of a new A$400 million delayed-draw subordinated notes facility
• Facility can be drawn in two tranches: A$250 million and A$150 million
• ~9-month and ~24-month availability periods for the two tranches, respectively
• 12-year non-call period and a final maturity in 2058
• Net proceeds earmarked to refinance existing subordinated notes callable in 2027 and 2028
• Facility fully underwritten by a cornerstone institutional investor group

What else do investors need to know?

The delayed-draw feature means Ampol can access funding flexibly as needed, with the option to issue the facility in two parts and the right to cancel the second tranche if desired. The subordinated notes are structured to secure long-term capital at fixed pricing, supporting stability in Ampol’s future refinancing plans.

Moody’s Investors Service is expected to assign 50% equity credit to the new notes, in line with Ampol’s existing subordinated debt. The offer is targeted only at institutional investors, with a closing date around 9 July 2026, subject to typical conditions.

What did Ampol management say?

Group Chief Financial Officer Greg Barnes said:

We’re delighted to announce this new financing facility, which utilises the same delayed-draw feature from our previous issue in December 2025. Investor commitments and issue pricing will be fixed upfront. Market conditions remain attractive and provide an opportune time to secure long-term capital, which is linked to our future hybrid refinancing initiatives. The delayed-draw feature gives Ampol significant flexibility with regards to issue timing, as well as use of proceeds and cancellation rights. The transaction is another example of our proactive approach to capital management.

What’s next for Ampol?

Ampol plans to use the facility to proactively refinance subordinated notes due in 2027 and 2028, aiming to optimise its balance sheet and preserve flexibility for future funding needs. Management is focused on securing stable, long-term capital to support its ongoing growth and sustainability initiatives, while enhancing its capital management strategy.

Ampol share price snapshot

Over the past 12 months, Ampol shares have risen 29%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.

View Original Announcement

The post Ampol launches new $400m subordinated notes facility appeared first on The Motley Fool Australia.

More reading

• Centuria Capital Group opens $35m retail offer, targets growth in AI and real estate
• Transurban Group announces major North America project expansion
• 5 things to watch on the ASX 200 on Friday
• What’s next for BHP shares? Broker forecasts revealed
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

It has been another big day for 4DMedical Ltd (ASX: 4DX) shareholders.

The ASX 200 healthcare stock is pushing higher on Friday after releasing an update that has kept investors interested.

At the time of writing, the 4DMedical share price is up 8.75% to $4.97.

The stock is now up around 40% over the past month and an incredible 1,800% since this time last year.

Here’s what 4DMedical announced to the market.

4DMedical gets TGA approval

According to the release, 4DMedical has received approval from the Therapeutic Goods Administration (TGA) for its CT:VQ product in Australia.

This means CT:VQ has now been included on the Australian Register of Therapeutic Goods, allowing it to be sold commercially across the country.

The company said CT:VQ is the world’s first non-contrast, CT-based ventilation-perfusion imaging solution.

The software helps doctors see how air and blood move through the lungs using standard CT scans. Essentially, patients can be assessed without the need for some nuclear medicine imaging methods.

4DMedical said the approval could support use across metropolitan, regional, and rural Australia, including areas with CT scanners but limited access to nuclear medicine services.

The company noted that CT:VQ is already approved in several major markets, including the US, Europe, the UK, Canada, and New Zealand.

What investors will be watching now

The approval gives 4DMedical a new market to work with, but investors will want to see how quickly that turns into adoption.

Although, there’s already some progress overseas.

In the United States, CT:VQ has been deployed at major clinical sites including Stanford, Cleveland Clinic, and the University of Miami.

The company has also signed an agreement with SimonMed Imaging, one of the largest outpatient radiology providers in the United States.

Back in Australia, the next step for the company is reimbursement.

Management said it is preparing an application to the Medical Services Advisory Committee to seek future Medicare Benefits Schedule reimbursement for CT.

If that’s approved, it could make the product much easier to be used more widely across our healthcare system.

Can the rally keep going?

Without doubt, the approval is a positive milestone.

But after rocketing 1,800% in 12 months, this isn’t a small company anymore flying under the radar.

4DMedical has a market capitalisation of around $2.8 billion, which means investors are already pricing in a much larger business.

And while that doesn’t mean the rally has gone too far, it certainly does raise the bar.

For now, the company needs to keep showing that CT can move from approvals and trial sites into broader commercial use.

The post This ASX 200 stock has soared 1,800%. Is there more to come? appeared first on The Motley Fool Australia.

More reading

• This ASX healthcare stock is up 1,900%. One top fundie wants more
• Up 1,700% and more, what’s next for these ASX 200 shares?
• Here are the top 10 ASX 200 shares today
• Here are the 10 most shorted ASX shares
• Healthcare shares led the ASX 200 last week. Is a sector comeback underway?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

When it comes to investing in the energy sector, Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) shares are often front of mind.

But there is another ASX energy stock that Bell Potter is recommending to shareholders.

Which ASX energy stock?

The stock Bell Potter is bullish on is Comet Ridge Ltd (ASX: COI).

It is an energy exploration and development company focused on the Mahalo Gas Hub in Queensland’s Bowen Basin.

Bell Potter notes that the company is raising up to $45 million. These funds will be used partly to settle its acquisition of Santos’ 42.86% interest in the Mahalo joint venture.

The broker highlights that this leaves it well-placed now to focus on its final investment decision (FID), which is due in FY 2027. It said:

COI is now targeting Gas Sales Agreements and releasing Mahalo Gas Project economics by the end of 2026 to support funding approvals and a Final Investment Decision by the end of the March 2027 quarter. On this timeline, COI see first gas production in late 2028.

The Mahalo development will leverage 676PJ of 2P Reserves plus 2C Contingent Resources, successful pilot wells and the permitting already received over some acreage. With the STO transaction now funded, COI must now turn its efforts to funding Mahalo’s development capital costs, the quantum of which will be highly dependent on the development scenarios and project economics now being considered.

Should you invest?

According to the note, Bell Potter has retained its speculative buy rating on the ASX energy stock with a reduced price target of 14 cents.

Based on its current share price of 9.9 cents, this implies potential upside of 41% for investors over the next 12 months.

To put that into context, a $2,000 investment would turn into approximately $2,800 by this time next year if the broker is on the money with its recommendation.

Commenting on its investment thesis, Bell Potter said:

Our COI valuation is based on COI’s Mahalo project which is one of the few development-ready gas projects capable of delivering near-term supply. We are positive on Australian east coast gas markets, with supply shortfalls likely to support higher prices. Funding the Mahalo development remains a risk. COI is a gas development company with prospective operations and cash flows only; our Speculative risk rating recognises this higher level of risk.

The post Bell Potter is tipping this ASX energy stock to rise 40% (It isn’t Woodside) appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• Crude oil falls below US$70 as ASX energy shares sell-off
• Why Judo Capital, Minerals 260, Santos, and Worley shares are dropping today
• Is the Woodside share price a buy in July?
• 5 things to watch on the ASX 200 on Thursday

Motley Fool contributor James Mickleboro has positions in Woodside Energy Group Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.